Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398492 | 1.00 | RARA (0.31) | RARARARBRARGPGRPDK2 | |
| SCHEMBL5406952 | 0.94 | RARB (0.30) | RARBRARGPGRRXRA | |
| SCHEMBL5406948 | 0.94 | RARB (0.30) | RARBRARGPGRRXRA | |
| SCHEMBL5406525 | 0.85 | RARB (0.32) | RARBRARGRXRA | |
| SCHEMBL5406530 | 0.85 | RARB (0.32) | RARBRARGRXRA | |
| SCHEMBL14440622 | 0.83 | NOTUM (0.37) | — | |
| SCHEMBL14543061 | 0.81 | RARA (0.30) | RARARARBRARG | |
| SCHEMBL5397192 | 0.79 | ALDH1A1 (0.36) | RARARARBRARGRXRA | |
| SCHEMBL14543060 | 0.79 | RARA (0.30) | RARARARBRARG | |
| SCHEMBL14543095 | 0.79 | PGR (0.32) | RARARARBRARGPGRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | claimed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | claimed |
| US-20070185057-A1 | Novel Indanone Compounds | SYMRISE GMBH & CO. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185057-A1 | Novel Indanone Compounds | SYMRISE GMBH & CO. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185057-A1 | Novel Indanone Compounds | CUTA, NISCH, TYR | RARA 1846/4885RARB 1465/4885RARG 1708/4885 |
| US-20020143203-A1 | Novel indanylidene compounds | CUTA, NISCH, ERCC4 | RARA 719/4885RARB 649/4885RARG 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.